CD40‐CD40 ligand

CD40 is a cell surface receptor that belongs to the tumor necrosis factor‐R (TNF‐R) family, and that was first identified and functionally characterized on B lymphocytes. Its critical role in T cell‐dependent humoral immune responses was demonstrated by patients with the hyper‐IgM syndrome, as well as by gene targeting in mice. However, in recent years it has become clear that CD40 is expressed much more broadly, including expression on monocytes, dendritic cells, endothelial cells, and epithelial cells. In addition, the CD40‐ligand (CD40‐L/CD154), a member of the TNF family, is also expressed more widely than activated CD4+ T cells only. Therefore it is now thought that CD40‐CD40‐L interactions play a more general role in immune regulation. Collectively these studies have culminated in pre‐clinical and clinical studies that are in progress. This article reviews recent developments in this field of research, with main emphasis on (1) structure and expression of CD40 and its ligand; (2) CD40 signal transduction; (3) in vitro function of CD40 on different cell types; and (4) in vivo functions of CD40/CD40‐L interactions. J. Leukoc. Biol. 67: 2–17; 2000.

[1]  J. Banchereau,et al.  The CD40 antigen and its ligand. , 1994, Annual review of immunology.

[2]  R J Armitage,et al.  Humoral immune responses in CD40 ligand-deficient mice , 1994, The Journal of experimental medicine.

[3]  S. Ju,et al.  Protection against Fas-dependent Thl-mediated apoptosis by antigen receptor engagement in B cells , 1995, Nature.

[4]  J. Banchereau,et al.  Within germinal centers, isotype switching of immunoglobulin genes occurs after the onset of somatic mutation. , 1996, Immunity.

[5]  R. Geha,et al.  Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. , 1997, Immunity.

[6]  J. Laman,et al.  CD40-CD40L interactions in atherosclerosis. , 1997, Immunology today.

[7]  S. Miller,et al.  Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. , 1999, The Journal of clinical investigation.

[8]  R. Flavell,et al.  In the absence of a CD40 signal, B cells are tolerogenic. , 1995, Immunity.

[9]  T. Horii,et al.  Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. , 1996, Immunity.

[10]  Yong‐jun Liu,et al.  Polymerase Chain Reaction Selects a Novel Disintegrin Proteinase from CD40-Activated Germinal Center Dendritic Cells , 1997, The Journal of experimental medicine.

[11]  W. Hammerschmidt,et al.  Epstein–Barr virus‐mediated B‐cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor , 1998, The EMBO journal.

[12]  T. Schumacher,et al.  CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.

[13]  J. Banchereau,et al.  Negative Selection of Human Germinal Center B Cells by Prolonged Bcr Cross-linking , 1996 .

[14]  Juswinder Singh,et al.  The role of polar interactions in the molecular recognition of CD40L with its receptor CD40 , 1998, Protein science : a publication of the Protein Society.

[15]  D. Taub,et al.  Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. , 1999, Blood.

[16]  A. Durandy,et al.  Recombinant Soluble Trimeric CD40 Ligand Is Biologically Active * , 1995, The Journal of Biological Chemistry.

[17]  S. Burrows,et al.  Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. , 1997, Journal of immunology.

[18]  D. Gray,et al.  CD40 ligand-transduced co-stimulation of T cells in the development of helper function , 1995, Nature.

[19]  J Bajorath,et al.  Immune regulation by CD40 and its ligand GP39. , 1996, Annual review of immunology.

[20]  P. Lipsky,et al.  TNF receptor-associated factor-3 signaling mediates activation of p38 and Jun N-terminal kinase, cytokine secretion, and Ig production following ligation of CD40 on human B cells. , 1998, Journal of immunology.

[21]  H. Ochs,et al.  Mutations of the CD40 ligand gene in 13 Japanese patients with X-linked hyper-IgM syndrome , 1997, Human Genetics.

[22]  Y. Hsu,et al.  Heteromultimeric Complexes of CD40 Ligand Are Present on the Cell Surface of Human T Lymphocytes* , 1997, The Journal of Biological Chemistry.

[23]  R. Noelle,et al.  The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells , 1998, Journal of leukocyte biology.

[24]  M. Crow,et al.  Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. , 1996, The Journal of clinical investigation.

[25]  T. Kipps,et al.  Acquired CD40-ligand deficiency in chronic lymphocytic leukemia , 1997, Nature Medicine.

[26]  E. Clark,et al.  Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. , 1996, Journal of immunology.

[27]  J. Karras,et al.  Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement. , 1997, Journal of immunology.

[28]  E. Kieff,et al.  A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. , 1998, Journal of immunology.

[29]  C. Maliszewski,et al.  Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion , 1992, The Journal of experimental medicine.

[30]  D. Baltimore,et al.  Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. , 1996, Immunity.

[31]  S. Kalled,et al.  Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. , 1998, Journal of immunology.

[32]  J. Banchereau,et al.  Human Dendritic Cells Skew Isotype Switching of CD40-activated Naive B Cells towards IgA1 and IgA2 , 1997, The Journal of experimental medicine.

[33]  R. Mitchell,et al.  CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. , 1997, Transplantation.

[34]  I. Weissman,et al.  Arrest of B lymphocyte terminal differentiation by CD40 signaling: mechanism for lack of antibody-secreting cells in germinal centers. , 1998, Immunity.

[35]  R. Zinkernagel,et al.  CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions , 1996, The Journal of experimental medicine.

[36]  D. Harlan,et al.  CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Aruffo,et al.  In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions , 1993, The Journal of experimental medicine.

[38]  R. Noelle,et al.  CD40 and its ligand in host defense. , 1996, Immunity.

[39]  J Bajorath,et al.  Detailed Comparison of Two Molecular Models of the Human CD40 Ligand with an X-ray Structure and Critical Assessment of Model-based Mutagenesis and Residue Mapping Studies* , 1998, The Journal of Biological Chemistry.

[40]  J. Thompson,et al.  2 A crystal structure of an extracellular fragment of human CD40 ligand. , 1995, Structure.

[41]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[42]  A. Heath,et al.  Enhancement of T cell-independent immune responses in vivo by CD40 antibodies , 1998, Nature Medicine.

[43]  Hao Wu,et al.  Structural basis for self-association and receptor recognition of human TRAF2 , 1999, Nature.

[44]  B. Ludewig,et al.  Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells , 1996, European journal of immunology.

[45]  J. Finkelstein,et al.  Disruption of the CD40-CD40 ligand system prevents an oxygen-induced respiratory distress syndrome. , 1998, The American journal of pathology.

[46]  G. Inghirami,et al.  Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. , 1992, Journal of immunology.

[47]  J. Bonnefoy,et al.  IgE versus IgG4 production can be differentially regulated by IL-10. , 1998, Journal of immunology.

[48]  L. Young,et al.  CD40 and epithelial cells: across the great divide. , 1998, Immunology today.

[49]  A. Fischer,et al.  Abnormal CD40-mediated activation pathway in B lymphocytes from patients with hyper-IgM syndrome and normal CD40 ligand expression. , 1997, Journal of immunology.

[50]  P. J. Belshaw,et al.  Cyclosporin A inhibits CD40 ligand expression in T lymphocytes. , 1994, The Journal of clinical investigation.

[51]  H. Engelmann,et al.  A novel function of CD40: induction of cell death in transformed cells , 1996, The Journal of experimental medicine.

[52]  D. Gray,et al.  CD40 ligand signals optimize T helper cell cytokine production: role in Th2 development and induction of germinal centers , 1998, European journal of immunology.

[53]  M. Daemen,et al.  CD40-CD40L interactions in atherosclerosis. , 2002, Trends in cardiovascular medicine.

[54]  E. Clark,et al.  Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation. , 1992, Journal of immunology.

[55]  R. Flavell,et al.  A central role of CD40 ligand in the regulation of CD4+ T-cell responses. , 1996, Immunology today.

[56]  P. Linsley,et al.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.

[57]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[58]  E. Kieff,et al.  Identification of TRAF6, a Novel Tumor Necrosis Factor Receptor-associated Factor Protein That Mediates Signaling from an Amino-terminal Domain of the CD40 Cytoplasmic Region* , 1996, The Journal of Biological Chemistry.

[59]  D. Harlan,et al.  Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates , 1999, Nature Medicine.

[60]  J. Christensen,et al.  CD40 ligand is pivotal to efficient control of virus replication in mice infected with lymphocytic choriomeningitis virus. , 1998, Journal of immunology.

[61]  I. Stamenkovic,et al.  A B‐lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. , 1989, The EMBO journal.

[62]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[63]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[64]  G. Sonenshein,et al.  Dominant signals leading to inhibitor kappaB protein degradation mediate CD40 ligand rescue of WEHI 231 immature B cells from receptor-mediated apoptosis. , 1998, Journal of immunology.

[65]  J. Woodgett,et al.  Cross‐linking CD40 on B cells preferentially induces stress‐activated protein kinases rather than mitogen‐activated protein kinases. , 1996, The EMBO journal.

[66]  V. D’Agati,et al.  Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. , 1997, Arthritis and rheumatism.

[67]  R. Ramsey‐Goldman,et al.  Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. , 1996, The Journal of clinical investigation.

[68]  G. Klaus,et al.  CD28 co-stimulation stabilizes the expression of the CD40 ligand on T cells. , 1998, International immunology.

[69]  C. Ware,et al.  Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[70]  D. Goeddel,et al.  I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[71]  S R Sprang,et al.  Modularity in the TNF-receptor family. , 1998, Trends in biochemical sciences.

[72]  J Bajorath,et al.  Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. , 1995, Biochemistry.

[73]  R. Kroczek,et al.  A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation , 1995, European journal of immunology.

[74]  P. Libby,et al.  Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.

[75]  E. Ingulli,et al.  Visualization of specific B and T lymphocyte interactions in the lymph node. , 1998, Science.

[76]  D. Parker,et al.  Differential coupling of membrane Ig and CD40 to the extracellularly regulated kinase signaling pathway. , 1998, Journal of Immunology.

[77]  L. Notarangelo,et al.  Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. , 1997, Journal of immunology.

[78]  W. Jusko,et al.  Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys. , 1998, The Journal of pharmacology and experimental therapeutics.

[79]  E. Krebs,et al.  p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes. , 1998, Journal of immunology.

[80]  H. Spits,et al.  A New Mechanism of NK Cell Cytotoxicity Activation: The CD40–CD40 Ligand Interaction , 1997, The Journal of experimental medicine.

[81]  K. Irvine,et al.  CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. , 1998, Journal of immunology.

[82]  M Vihinen,et al.  CD40lbase: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome. , 1996, Immunology today.

[83]  R. Flavell,et al.  CD40 and CD154 in cell-mediated immunity. , 1998, Annual review of immunology.

[84]  D. Baltimore,et al.  Involvement of CRAF1, a relative of TRAF, in CD40 signaling , 1995, Science.

[85]  P. Linsley,et al.  Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. , 1997, Transplantation.

[86]  L. Davis,et al.  The CD40 ligand expressed by human B cells costimulates B cell responses. , 1995, Journal of immunology.

[87]  I. Maclennan,et al.  A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex , 1995, The Journal of experimental medicine.

[88]  C. Patrosso,et al.  Organization of the human CD40L gene: implications for molecular defects in X chromosome-linked hyper-IgM syndrome and prenatal diagnosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[89]  D. Goeddel,et al.  TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40 , 1995, Science.

[90]  J. Inoue,et al.  TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[91]  P. Casali,et al.  CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells. , 1998, Immunity.

[92]  M. Glennie,et al.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help , 1999, Nature Medicine.

[93]  J. Sun,et al.  Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. , 1996, Immunity.

[94]  R. Insel,et al.  Telomerase is up-regulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro. , 1997, Journal of immunology.

[95]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[96]  François Mach,et al.  Expression of Stromelysin-3 in Atherosclerotic Lesions: Regulation via CD40–CD40 Ligand Signaling In Vitro and In Vivo , 1999, The Journal of experimental medicine.

[97]  M. Kehry,et al.  CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. , 1998, Biochemistry.

[98]  N. Yoshida,et al.  The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. , 1994, Immunity.

[99]  C. Larsen,et al.  The CD40 pathway in allograft rejection, acceptance, and tolerance. , 1997, Current opinion in immunology.

[100]  H. Bien,et al.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 , 1999, Nature Medicine.

[101]  J. Holton,et al.  Crystallographic analysis of CD40 recognition and signaling by human TRAF2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[102]  R. Flavell,et al.  Mice deficient for the CD40 ligand. , 1994, Immunity.

[103]  K. Okazaki,et al.  Tumor Necrosis Factor Receptor–associated Factor 6 (TRAF6) Stimulates Extracellular Signal–regulated Kinase (ERK) Activity in CD40 Signaling Along a Ras-independent Pathway , 1998, The Journal of experimental medicine.

[104]  Christophe Caux,et al.  Dendritic Cells Enhance Growth and Differentiation of CD40-activated B Lymphocytes , 1997, The Journal of experimental medicine.

[105]  G. Bishop,et al.  Characterization of CD40 signaling determinants regulating nuclear factor-kappa B activation in B lymphocytes. , 1997, Journal of immunology.

[106]  P. Linsley,et al.  Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. , 1998, Transplantation.

[107]  D. Taub,et al.  Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand , 1999 .

[108]  P. Libby,et al.  Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[109]  T. Watts,et al.  Cyclic-AMP modulates downstream events in CD40-mediated signal transduction, but inhibition of protein kinase A has no direct effect on CD40 signaling. , 1997, Journal of immunology.

[110]  E. Clark,et al.  Molecular and biological characterization of a murine ligand for CD40 , 1992, Nature.

[111]  D. Cockayne,et al.  Genomic structure and chromosomal mapping of the murine CD40 gene. , 1992, Journal of immunology.

[112]  A. Aruffo,et al.  CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[113]  S. Kalled,et al.  CD40-CD40 ligand interaction in autoimmune disease. , 1997, Arthritis and rheumatism.

[114]  S. Reed,et al.  CD40 ligand is required for protective cell-mediated immunity to Leishmania major. , 1996, Immunity.

[115]  P. Borrow,et al.  CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response , 1996, The Journal of experimental medicine.

[116]  J. Banchereau,et al.  Generation of memory B cells and plasma cells in vitro , 1995, Science.

[117]  J. Bonnefoy,et al.  Interleukin-7 (IL-7) enhances class switching to IgE and IgG4 in the presence of T cells via IL-9 and sCD23. , 1998, Blood.

[118]  I. Stamenkovic,et al.  The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co‐stimulatory activity. , 1992, The EMBO journal.

[119]  J. Suttles,et al.  Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. , 1996, Journal of immunology.

[120]  J. Suttles,et al.  The many roles of CD40 in cell-mediated inflammatory responses. , 1996, Immunology today.

[121]  M. Boguski,et al.  A novel RING finger protein interacts with the cytoplasmic domain of CD40. , 1994, The Journal of biological chemistry.

[122]  B. Cherayil,et al.  CD40-mediated signals inhibit the binding of TNF receptor-associated factor 2 to the CD40 cytoplasmic domain. , 1997, Journal of immunology.

[123]  J. Banchereau,et al.  CD40-CD40 ligand: a multifunctional receptor-ligand pair. , 1996, Advances in immunology.

[124]  E. Schattner,et al.  Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. , 1998, Blood.

[125]  R. Flavell,et al.  Expansion or Elimination of B Cells In Vivo: Dual Roles for CD40- and Fas (CD95)-Ligands Modulated by the B Cell Antigen Receptor , 1996, Cell.

[126]  T. Strom,et al.  Increased CD40 ligand gene expression during human renal and murine islet allograft rejection. , 1998, Transplantation.

[127]  J. Banchereau,et al.  CD40 Ligation on Human Cord Blood CD34+Hematopoietic Progenitors Induces Their Proliferation and Differentiation into Functional Dendritic Cells , 1997, The Journal of experimental medicine.

[128]  C. Snapper,et al.  Efficient recombination of a switch substrate retrovector in CD40-activated B lymphocytes: implications for the control of CH gene switch recombination. , 1998, Journal of immunology.